Background: Glycoprotein IIb/IIIa (aIIb/b 3 ) is involved in platelet adhesion, and triggers a series of intracellular signaling cascades, leading to platelet shape change, granule secretion, and clot retraction.
Introduction
Activation of platelets by various agonists (i.e., adenosine diphosphate, collagen, thrombin) causes shape change, granule secretion, and platelet aggregation. These signaling events are mediated by the activation of integrins such as glycoprotein IIb/IIIa (aIIb/b 3 ). Activated aIIb/b 3 interacts with its ligands (i.e., fibrinogen, fibronectin), then causes Ca 2þ mobilization, granule secretion, and clot retraction [1e3] , and subsequently augments the formation of thrombus.
Vasodilator-stimulated phosphoprotein (VASP) in platelets is associated with actin filament dynamics and focal adhesions, but its phosphorylated-forms (Ser , Ser 239 ) weaken the affinity of VASP for actin filaments to block the binding of adhesive proteins to aIIb/ b 3 [4, 5] . Accordingly, phosphorylation of VASP could be used to appreciate the binding of adhesive proteins to aIIb/b 3 , and contribute to estimating the antithrombotic effect of a certain compound. For instance, antiplatelet compounds such as p-terphenyl curtisian E and quercetin lead to VASP phosphorylation [6, 7] . In addition, abciximab, eptifibatide, tirofiban, and lamifiban are known to inhibit the activation of aIIb/b 3 [8, 9] .
Ginseng, the root of Panax ginseng Meyer, has been used frequently in traditional Oriental medicine. Ginsenoside Ro (GRo; Fig. 1 ), an oleanane-type saponin, in P. ginseng Meyer [10, 11] , is known to inhibit fibrin formation [12, 13] , and has no inhibitory effect on collagen-elevated platelet aggregation [14] . Until now, there has been no report on the antiplatelet mechanism of G-Ro. In this study, we found that G-Ro stimulates VASP (Ser  157 ) phosphorylation in a cyclic adenosine monophosphate (cAMP)-dependent manner, which attenuates the binding of fibrinogen to aIIb/b 3 , and clot retraction in thrombin-activated human platelets. 
Materials and methods

Materials
Preparation of washed human platelets
Human platelet-rich plasma with acid-citrate-dextrose solution (0.8% citric acid, 2.2% sodium citrate, 2.45% glucose) was supplied from Korean Red Cross Blood Center (Changwon, Korea). To remove red blood cells and white blood cells, it was centrifuged for 10 min at 250g and 10 min at 1,300g. The platelets were washed twice using washing buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO 3 , 0.36mM NaH 2 PO 4 , 5.5mM glucose, and 1mM Na 2 EDTA, pH 6.5), then resuspended in suspension buffer (138mM NaCl, 2.7mM KCl, 12mM NaHCO 3 , 0.36mM NaH 2 PO 4 , 0.49mM MgCl 2 , 5.5mM glucose, 0.25% gelatin, pH 6.9) to a final concentration of 5 Â 10 8 /mL. All of the above procedures were performed at 25 C to maintain platelet activity. Approval (PIRB12-072) for these experiments was received from the National Institute for Bioethics Policy Public Institutional Review Board (Seoul, Korea).
Determination of platelet aggregation
Washed human platelets (10 8 /mL) were preincubated with or without G-Ro in the reaction system containing 2mM of CaCl 2 for 3 min at 37 C, then stimulated with thrombin (0.05 U/mL). The aggregation was performed for 5 min using an aggregometer (Chrono-Log Corporation, Havertown, PA, USA) at a constant stirring speed of 1,000 rpm. Each aggregation rate was determined as an increase in light transmission. G-Ro was dissolved in platelet suspension buffer (pH 6.9), and suspension buffer was used as the reference (transmission 0) The platelet aggregation was conducted in the presence of Alexa Flour 488-human fibrinogen (30 mg/mL) for 5 min at 37 C.
The reaction was stopped by the addition of 0.5% paraformaldehyde in cold phosphate-buffered saline (pH 7.4), and the aforementioned procedures were implemented under dark conditions. The assay of fibrinogen binding was carried out using flow cytometry (BD Biosciences, San Jose, CA, USA), and its degree was determined with CellQuest software (BD Biosciences).
Assay of platelet-mediated fibrin clot retraction
Human platelet-rich plasma, 250 mL, was preincubated with or without G-Ro (300mM) for 10 min at 37 C, and incubated with thrombin (0.05 U/mL) for 10 min and 20 min at 37 C. Photographs of the fibrin clot were taken by a digital camera, and its area (at 20 min) was measured by NIH Image J Software (version 1.46, National Institutes of Health, Bethesda, Maryland, USA). Percentage of clot retraction was calculated as follows:
retraction ð%Þ by thrombin ¼ ðcontrol area À thrombin areaÞ =control area Â 100: ð1Þ
Measurement of cAMP and cGMP
After platelet aggregation, 80% ice cold ethanol was added to terminate the reaction, and cAMP and cGMP were extracted three times with 80% ice cold ethanol. The extracts tubes were dried by nitrogen gas, and subsequently dissolved with assay buffer (Cayman Chemical, Ann Arbor, MI, USA). The level of cAMP and Fig. 1 . Chemical structure of ginsenoside Ro. Ginsenoside Ro (G-Ro), an oleanane-type saponin, is contained in Panax ginseng Meyer [10, 11] , and is composed of oleanolic acid as aglycone, and two glucose and one glucuronic acid as sugar component [10] .
cGMP was determined with Synergy HT Multi-Model Microplate Reader (BioTek Instruments, Winoosku, VT, USA).
Statistical analysis
The experimental results are indicated as the mean AE standard deviation accompanied by the number of observations. Data were determined by analysis of variance. If this analysis showed significant differences among the group means, then each group was compared by the Newman-Keuls method. Statistical analysis was carried out according to the SPSS 21.0.0.0 (SPSS Inc., Chicago, IL, USA). A p value < 0.05 was considered to be statistically significant.
Results
Effects of G-Ro on thrombin-induced human platelet aggregation
Because 0.05 U/mL of thrombin maximally aggregated human platelets [15] , this concentration was used to investigate the antiplatelet effect of G-Ro (Fig. 1) . In unstimulated platelets, the light transmission in response to various concentrations of G-Ro (50mM, 100mM, 200mM, 300mM) was 1.3 AE 0.6% (at 50mM of G-Ro), 1.7 AE 0.6% (at 100mM of G-Ro), 1.3 AE 0.6% (at 200mM of G-Ro), and 1.7 AE 0.6% (at 300mM of G-Ro), which were not significantly different from that (1.0 AE 0.0%) in resting platelets without G-Ro (Fig. 2) . Thrombin increased light transmission and the aggregation rate was 90.7 AE 1.2% (Fig. 2) . However, G-Ro dose-dependently (50mM, 100mM, 200mM, 300mM) reduced thrombin-elevated light transmission, meaning G-Ro inhibits thrombin-induced platelet aggregation (Fig. 2) .
Effects of G-Ro on VASP phosphorylation
In intact platelets, 46 kDa dephosphoprotein only of VASP was observed (Fig. 3A, Lane 1 ) [16] . Because G-Ro dose (100, 200, 300 mM)-dependently inhibited up to 26.9 AE 0.6% (by 100 mM GRo), 56.0 AE 2.8% (by 200 mM G-Ro), and 88.4 AE 1.7% (by 300 mM GRo) in thrombin-induced platelet aggregation (Fig. 2) , we investi- (Fig. 3B) . However, G-Ro did not affect phosphorylation of VASP (Ser 239 ; Fig. 3C ), even though G-kinase activator 8-Br-cGMP, a positive control, phosphorylated VASP (Ser 239 ; Fig. 3C , Lane 6). This reflects the result that G-Ro does not increase the cGMP level (Table 1) , and subsequently involve in phosphorylation of VASP (Ser
239
) in thrombin-activated platelets. Because G-Ro increased the cAMP level (Table 1) (Table 1) , and subsequently phosphorylates VASP (Ser 157 ) in thrombin-activated platelets.
Effects of G-Ro on the production of cAMP and cGMP
Because it is well established that cAMP and cGMP stimulate VASP phosphorylation [17, 18] , we investigated the effect of G-Ro on the production of cAMP and cGMP in thrombin-induced platelet aggregation. As shown in Table 1 , G-Ro increased the cAMP level in thrombin-induced platelet aggregation, but did not increase the level of cGMP. 38.4 AE 3.4% (at eptifibatide 50mM) and 35.7 AE 2.6% (at GR144053 50mM), which were almost equal to that (37.6 AE 0.6%) by G-Ro (200mM; Fig. 4B ). As G-Ro increased the cAMP level (Table 1) and VASP (Ser 157 ) phosphorylation (Fig. 3B) , if the inhibition of fibrinogen binding by G-Ro (Fig. 4B) resulted from cAMP/A-kinasemediated VASP (Ser 157 ) phosphorylation (Fig. 3B) , it is thought that G-Ro-decreased fibrinogen binding would be increased by the A-kinase inhibitor. To confirm that cAMP/A-kinase had an inhibitory effect on G-Ro-blocked fibrinogen binding, we examined the effect of the A-kinase inhibitor on inhibition of fibrinogen binding by 300mM of G-Ro (Fig. 4B ) that potently inhibited fibrinogen binding. The A-kinase inhibitor Rp-8-Br-cAMPS increased G-Roinhibited fibrinogen binding to aIIb/b 3 in thrombin-activated platelets (Figs. 5A , 5B), and its degree was increased to 179.2% as compared with that (10.6 AE 1.3%) by G-Ro (300mM) plus thrombin ( Table 2) . 
Effects of G-Ro on
Effects of G-Ro on retraction of fibrin clot
The binding of fibrinogen is known to stimulate clot retraction to intensify the formation of thrombus [19e21] . Thus, we investigated whether G-Ro inhibits clot retraction. Thrombin reaction time-dependently (10 min and 20 min) accelerated the clot retraction (Fig. 6A) , and its degree (at 20 min) was increased to 90% compared to that (55.4 AE 1.3 mm 2 ) without thrombin, control (Fig. 6B) . However, G-Ro very potently inhibited clot retraction by thrombin (Fig. 6A) , which was attenuated up to 740% against that (5.5 AE 0.8 mm 2 ) by thrombin (Fig. 6B ).
Discussion
Intracellular cAMP and cGMP phosphorylate inositol 1,4,5-triphosphate receptor type I (IP 3 RI) and VASP. The )-50 kDa phosphorylation in the presence of an A-kinase inhibitor (Rp-8-Br-cAMPS). Lane 1, intact platelets (base); Lane 2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 U/mL) þ G-Ro (300mM); Lane 4, thrombin (0.05 U/mL) þ G-Ro (300mM) þ Rp-8-Br-cAMPS (250 mM); and Lane 5, thrombin (0.05 U/mL) þ pCPT-cAMP (1mM). Western blotting was performed as described in the "Materials and methods" section. Data are presented as mean AE SD (n ¼ 4). * p < 0.05 versus the thrombin-stimulated human platelets. ** p < 0.05 versus the thrombin-stimulated human platelets in the presence of G-Ro (300mM).
Table 1
Effects of ginsenoside Ro (G-Ro) on cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) production 
Data are presented as mean AE standard deviation (n ¼ 4) *p < 0.05 versus the thrombin-stimulated human platelets 1) Determination of cAMP and cGMP was carried out as described in the "Materials and methods" section Table 2 Effects of ginsenoside Ro (G-Ro) on changes of fibrinogen binding 1) Fibrinogen Binding (%) ] i mobilization by phosphorylating IP 3 RI in a cAMP-dependent manner [22] . This means that G-Ro may be involved in inhibition of fibrinogen ) is phosphorylated by cGMP/G-kinase [17, 18] . In reality, G-Ro cAMPdependently stimulated the phosphorylation of VASP (Ser The fibrinogen binding to aIIb/b 3 intensifies the formation of thrombus [19] by stimulating the retraction of the fibrin clot, which accelerates the progression of atherosclerosis [24, 25] . Therefore, it is natural that G-Ro, inhibiting the fibrinogen binding, potently inhibits the retraction of the fibrin clot.
Platelet aggregation is connected to inflammation, a cause of atherosclerosis, and its associated proteins (platelet-derived growth factor, vascular endothelial growth factor, p-selectin, interleukin 1b, etc.) are secreted out of a-granules [26e33] . Even though G-Ro phosphorylates VASP (Ser 157 ), it inhibits fibrinogen binding to attenuate thrombin-induced platelet aggregation, and fibrin clot retraction. If G-Ro dose not attenuate inflammation by leukocytes, antiplatelet effects by G-Ro would be doubtful. It is known that p-selectin is released by Ca 2þ , and subsequently interacts with monocyte to trigger inflammation [34] . G-Ro in a Ca 2þ -antagonistic action inhibited thrombin-induced expression of pselectin [22] , which means that the decrease of Ca 2þ level by G-Ro might involve in inhibition of inflammation by suppressing thrombin-induced p-selectin secretion. This is also evidenced by results that G-Ro had anti-inflammatory activity in vivo and in vitro [35, 36] . These reports [35, 36] indicate that G-Ro may protect against thrombosis and atherosclerosis without inflammation. The concentrations of G-Ro with antiplatelet effects (50e300 mM) are very low as compared with that 1mM of G-Ro attenuated arachidonic acid-induced platelet aggregation [12] . It is reported that G-Ro (10e50 mg/kg body weight-rat) administration activates fibrinolysis, an index of inhibition in fibrin thrombi [13] . Even (control À thrombin)/control Â 100. 2) [control À (thrombin þ G-Ro)]/control Â 100. 3) [thrombin À (thrombin þ G-Ro)]/thrombin Â 100. Data are presented as mean AE standard deviation (n ¼ 4). * p < 0.05 versus the thrombin-stimulated human platelets.
though 300 mM (about 287 mg/kg) of G-Ro (MW. 957.1) has the anticlot retraction effect, it is unknown whether thrombin-induced clot retraction would also be inhibited in vivo through administration. However, because thrombin stimulates platelet aggregation and fibrin formation, it is thought that G-Ro 300mM (287 mg/kg) would be involved in attenuation of fibrin clot retraction.
In conclusion, we found inhibitory effects of G-Ro on fibrinogen binding to aIIb/b 3 , and clot retraction, which is mediated by cAMPdependent phosphorylation of VASP (Ser  157 ) . From this study, we suggest that G-Ro is a novel compound of P. ginseng which inhibits fibrinogen binding to aIIb/b 3 .
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